Patent · US Active

Compounds (immunorhelins)

US11434258B2 · kind B2 · utility

0Cited by
3References
12Claims
0Family size

Assignee

Inventors

Key dates

Filing dateJan 19, 2018
Grant dateSep 6, 2022
Priority date
Expiry dateJul 13, 2038

Classification

  • Technology area (CPC A)Human Necessities
  • CPC primaryA61K38/00
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

The present invention provides immune stimulating peptides (immunorhelins) capable of stimulating GnRH receptors when dosed to human patients or cells. These immunorhelins have utility in treating viral diseases and cancer.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.